The solubility of a drug can significantly impact its bioavailability, absorption rate, and ultimately, its effectiveness as a therapeutic agent.

Sanofi has terminated its study of tusamitamab ravtansine due to a Phase 3 trial in second-line NSCLC failing to achieve its main goal.

D2 receptor agonists are drugs that activate the D2 subtype of dopamine receptors, used in treating conditions like Parkinson’s disease and hyperprolactinemia.

GSK plc has entered an exclusive partnership with Hansoh Pharma to co-develop and market HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3 with a clinically proven topoisomerase inhibitor payload for serious medical conditions.

Prodrugs are pharmacologically inactive compounds that are converted into an active drug after administration within the body.

Aurinia Pharmaceuticals Inc. announced it filed an IND application for AUR200 with the FDA to advance its development.

NK1 antagonists are drugs that block the neurokinin-1 receptor, aiding in the treatment of nausea, vomiting, and psychiatric disorders.

Merck announced it got an FDA Complete Response Letter regarding its New Drug Application for gefapixant.

The terms New Molecular Entity (NME) and New Chemical Entity (NCE) are sometimes used interchangeably; however, they are distinct.

Rallybio Corporation revealed early Phase 1 trial results for RLYB116, a novel drug with prolonged action and subcutaneous administration in low volumes.

Melatonin receptor agonists are drugs that activate melatonin receptors, aiding in the treatment of sleep disorders.

Almirall S.A. has recently launched a phase I clinical trial to assess the safety profile, pharmacokinetic properties, immunogenic potential, and pharmacodynamic effects of ALM223.